Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizophreniform disorder

Psychoneuroendocrinology

Volumn 33, Issue 2, 2008, Pages 255-259

  Duval, Fabrice ^a   Guillon, Marie Sabine ^a   Mokrani, Marie Claude ^a   Crocq, Marc Antoine ^a   Garcia Duarte, Frederico ^a  

^a Centre Hospitalier de Rouffach   (France)

Author keywords

9 Hydroxyrisperidone; Adolescents; Prolactin; Risperidone; Schizophreniform disorder

Indexed keywords

PALIPERIDONE; PROLACTIN; RISPERIDONE;

ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HORMONE RELEASE; HOSPITALIZATION; HUMAN; HYPOGONADISM; MALE; MONOTHERAPY; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIFORM DISORDER; WEIGHT GAIN;

ADOLESCENT; ADOLESCENT MEDICINE; AGE FACTORS; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOXAZOLES; MALE; PROLACTIN; PSYCHOTIC DISORDERS; PYRIMIDINES; RISPERIDONE;

EID: 38349155532     PISSN: 03064530     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2007.10.010     Document Type: Article

References (36)

1. Aman M.G., De Smedt G., Derivan A., Lyons B., and Findling R.L. Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am. J. Psychiatry 159 (2002) 1337-1346
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. fourth ed (1994), American Psychiatric Press, Washington pp. 290-292
3. Anderson G.M., Scahill L., McCracken J.T., McDougle C.J., Aman M.G., Tierney E., Arnold L.E., Martin A., Katsovich L., Posey D.J., Shah B., and Vitiello B. Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol. Psychiatry 61 (2007) 545-550
4. Becker A.L., and Epperson C.N. Female puberty: clinical implications for the use of prolactin-modulating psychotropics. Child. Adolesc. Psychiatr. Clin. N. Am. 15 (2006) 207-220
5. Bowden C.R., Viona S.J., Woestenborghs R., de Coster R., and Heykants J. Stimulation by risperidone of rat prolactin secretion in vivo and in cultured pituitary cells in vitro. J. Pharmacol. Exp. Ther. 262 (1992) 699-706
6. Dunbar F., Kusumakar V., Daneman D., and Schulz M. Growth and sexual maturation during long-term treatment with risperidone. Am. J. Psychiatry 161 (2004) 918-920
7. Duval F., Chokmani N., Mokrani M.C., He J., and Macher J.P. Prolactin response to oral and long-acting forms of risperidone in schizophrenic patients. Eur. Neuropsychopharmacol. 16 (2006) S440
8. Eberhard J., Lindström E., Holstad M., and Levander S. Prolactin level during 5 years of risperidone treatment in patients with psychotic disorders. Acta Psychiatr. Scand. 115 (2007) 268-276
9. Findling R.L., and McNamara N.K. Atypical antipsychotics in the treatment of children and adolescents: clinical applications. J. Clin. Psychiatry 65 Suppl. 6 (2004) 30-44
10. Findling R.L., Kusumakar V., Daneman D., Moshang T., De Smedt G., and Binder C. Prolactin levels during long-term risperidone treatment in children and adolescents. J. Clin. Psychiatry 64 (2003) 1362-1369
11. Findling R.L., Aman M.G., Eerdekens M., Derivan A., and Lyons B. Risperidone Disruptive Behavior Study Group. Long-term, open-label study of risperidone in children with severe disruptive behaviors and below-average IQ. Am. J. Psychiatry 161 (2004) 677-684
12. Findling R.L., Steiner H., and Weller E.B. The use of antipsychotics in children and adolescents. J. Clin. Psychiatry 66 (2005) 29-40
13. First M.B., Spitzer R.L., Gibbon M., and Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I). Clinician edition (1997), American Psychiatric Press, Washington
14. Gagliano A., Germano E., Pustorino G., Impallomeni C., D'Arrigo C., Calamoneri F., and Spina E. Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. J. Child. Adolesc. Psychopharmacol. 14 (2004) 39-47
15. Grumbach M.M. The neuroendocrinology of human puberty revisited. Horm. Res. 57 Suppl. 2 (2002) 2-14
16. Haddad P.M., and Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64 (2004) 2291-2314
17. Halbreich U., and Kahn L.S. Hyperprolactinemia and schizophrenia: mechanisms and clinical aspects. J. Psychiatr. Pract. 9 (2003) 344-353
18. Hellings J.A., Zarcone J.R., Valdovinos M.G., Reese R.M., Gaughan E., and Schroeder S.R. Risperidone-induced prolactin elevation in a prospective study of children, adolescents, and adults with mental retardation and pervasive developmental disorders. J. Child. Adolesc. Psychopharmacol. 15 (2005) 885-892
19. Kapur S., Langois X., Vinken P., Megens A.A., de Coster R., and Andrews J.S. The differential effects of atypical anti-psychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J. Pharmacol. Exp. Ther. 302 (2002) 1129-1134
20. Knegtering R., Baselmans P., Castelein S., Bosker F., Bruggeman R., and van den Bosch R.J. Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am. J. Psychiatry 162 (2005) 1010-1012
21. Leysen J.E., Janssen P.M., Megens A.A., and Schotte A. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J. Clin. Psychiatry 55 Suppl. (1994) 5-12
22. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., and Elgen K. The UKU Side Effect Rating Scale: a new comprehensive rating scale for psychotropic drugs and cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand. Suppl. 334 (1987) 1-100
23. Melkersson K.I. Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite. Hum. Psychopharmacol. 21 (2006) 529-532
24. Mozes T., Ebert T., Michal S.E., Spivak B., and Weizman A. An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia. J. Child. Adolesc. Psychopharmacol. 16 (2006) 393-403
25. Pappagallo M., and Silva M. The effect of atypical antipsychotic agents on prolactin levels in children and adolescents. J. Child. Adolesc. Psychopharmacol. 14 (2004) 359-371
26. Research Units on Pediatric Psychopharmacology Autism Network. Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am. J. Psychiatry 162 (2005) 1361-1369
27. Reyes M., Buitelaar J., Toren P., Augustyns I., and Eerdekens M. A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am. J. Psychiatry 163 (2006) 402-410
28. Robertson-Plouch C., Carlson G., DelBello M., Findling R., Kowatch R., Schulz C., Kryzhanovskaya L., Xu W., Carlson J., and Tohen M. Changes in prolactin in adolescents with schizophrenia or bipolar disorder I during treatment with olanzapine: a pooled analysis of 4 study. Biol. Psychiatry 61 (2007) 170S
29. Sasaki F. Changes with age in the number and size of anterior pituitary cells in female mice from suckling to adulthood. J. Endocrinol. 117 (1988) 5-10
30. Staller J. The effect of long-term antipsychotic treatment on prolactin. J. Child. Adolesc. Psychopharmacol. 16 (2006) 317-326
31. Stevens J.R., Kymissis P.I., and Baker A.J. Elevated prolactin levels in male youths treated with risperidone and quetiapine. J. Child. Adolesc. Psychopharmacol. 15 (2005) 893-900
32. Szarfman A., Tonning J.M., Levine J.G., and Doraiswamy P.M. Atypical antipsychotics and pituitary tumors: a pharmacovigilance study. Pharmacotherapy 26 (2006) 748-758
33. Troost P.W., Lahuis B.E., Hermans M.H., Buitelaar J.K., van Engeland H., Scahill L., Minderaa R.B., and Hoekstra P.J. Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. J. Clin. Psychopharmacol. 27 (2007) 52-57
34. Wudarsky M., Nicolson R., Hamburger S.D., Spechler L., Gochman P., Bedwell J., Lenane M.C., and Rapoport J.L. Elevated prolactin in pediatric patients on typical and atypical antipsychotics. J. Child. Adolesc. Psychopharmacol. 9 (1999) 239-245
35. Zalsman G., Carmon E., Martin A., Bensason D., Weizman A., and Tyano S. Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. J. Child. Adolesc. Psychopharmacol. 13 (2003) 319-327
36. Zhou Z.L., Li X., Peng H.Y., Yu X.Y., Yang M., Su F.L., Wang F., Zhu R.H., Deng C.Y., Lin Q.X., Wang C.Y., Li W.B., Lin S.G., and Li H.D. Multiple dose pharmacokinetics of risperidone and 9-hydroxyrisperidone in Chinese female patients with schizophrenia. Acta Pharmacol. Sin. 27 (2006) 381-386